Aberrant methylation of imprinted genes is associated with negative hormone receptor status in invasive breast cancer

International Journal of Cancer

Volumn 137, Issue 3, 2015, Pages 537-547

  Barrow, Timothy M ^a,b   Barault, Ludovic ^a,g   Ellsworth, Rachel E ^c   Harris, Holly R ^a   Binder, Alexandra M ^a   Valente, Allyson L ^d   Shriver, Craig D ^e   Michels, Karin B ^a,b,f  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF FREIBURG   (Germany)

^c Henry M Jackson Foundation for the Advancement of Military Medicine   (United States)

^d WINDBER RESEARCH INSTITUTE   (United States)

^e WALTER REED ARMY MEDICAL CENTER   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^g CANDIOLO CANCER INSTITUTE   (Italy)

Author keywords

breast cancer; DNA methylation; genomic imprinting; hormone receptor; pyrosequencing

Indexed keywords

ESTROGEN RECEPTOR ALPHA; PROGESTERONE RECEPTOR A; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GROWTH FACTOR RECEPTOR BOUND PROTEIN 10; PROGESTERONE RECEPTOR; SOMATOMEDIN B;

ADULT; AGE; ALLELE; ARTICLE; BENIGN TUMOR; BLOOD SAMPLING; BODY MASS; BREAST CANCER; CANCER DIAGNOSIS; CANCER PATIENT; CANCER TISSUE; CONTROLLED STUDY; DIRAS3 DMR GENE; DNA METHYLATION; ETHNICITY; FAMILY HISTORY; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GRB10 ICR GENE; H19 ICR GENE; HUMAN; HUMAN TISSUE; IGF2 DMR0 GENE; IGF2 DMR2 GENE; KVDMR GENE; MAJOR CLINICAL STUDY; MENOPAUSE; MEST ICR GENE; PEG3 DMR GENE; PRIORITY JOURNAL; PYROSEQUENCING; SNRPN GENE; TUMOR INVASION; BREAST DISEASE; BREAST TUMOR; CANCER STAGING; CASE CONTROL STUDY; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; GENOME IMPRINTING; MIDDLE AGED; PATHOLOGY; RISK FACTOR;

ALLELES; BREAST DISEASES; BREAST NEOPLASMS; CASE-CONTROL STUDIES; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMIC IMPRINTING; GRB10 ADAPTOR PROTEIN; HUMANS; INSULIN-LIKE GROWTH FACTOR II; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS;

EID: 84929507363     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29419     Document Type: Article

References (49)

1. Cerrato F, Sparago A, Verde G, et al., Different mechanisms cause imprinting defects at the IGF2/H19 locus in Beckwith-Wiedemann syndrome and Wilms' tumour. Hum Mol Genet 2008; 17: 1427-35.
2. Rabinovitz S, Kaufman Y, Ludwig G, et al., Mechanisms of activation of the paternally expressed genes by the Prader-Willi imprinting center in the Prader-Willi/Angelman syndromes domains. Proc Natl Acad Sci U S A 2012; 109: 7403-8.
3. Feng W, Shen L, Wen S, et al., Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res 2007; 9: R57.
4. Feng W, Marquez RT, Lu Z, et al., Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer 2008; 112: 1489-502.
5. Dalai I, Missiaglia E, Barbi S, et al., Low expression of ARHI is associated with shorter progression-free survival in pancreatic endocrine tumors. Neoplasia 2007; 9: 181-3. [P MC][17401457]
6. Lin D, Cui F, Bu Q, et al., The expression and clinical significance of GTP-binding RAS-like 3 (ARHI) and microRNA 221 and 222 in prostate cancer. J Int Med Res 2011; 39: 1870-5.
7. Li Y, Meng G, Guo QN,. Changes in genomic imprinting and gene expression associated with transformation in a model of human osteosarcoma. Exp Mol Pathol 2008; 84: 234-9.
8. Cui H, Cruz-Correa M, Giardiello FM, et al., Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 2003; 299: 1753-5.
9. Feinberg AP, Irizarry RA., Evolution in health and medicine Sackler colloquium: stochastic epigenetic variation as a driving force of development, evolutionary adaptation, and disease. Proc Natl Acad Sci U S A 2010; 107 (Suppl 1): 1757-64.
10. Novakovic B, Yuen RK, Gordon L, et al., Evidence for widespread changes in promoter methylation profile in human placenta in response to increasing gestational age and environmental/stochastic factors. BMC Genom 2011; 12: 529.
11. Hansen KD, Timp W, Bravo HC, et al., Increased methylation variation in epigenetic domains across cancer types. Nat Genet 2011; 43: 768-75.
12. Teschendorff AE, Jones A, Fiegl H, et al., Epigenetic variability in cells of normal cytology is associated with the risk of future morphological transformation. Genome Med 2012; 4: 24.
13. Bentzon N, Düring M, Rasmussen BB, et al., Prognostic effect of estrogen receptor status across age in primary breast cancer. Int J Cancer 2008; 122: 1089-94.
14. Foulkes WD, Smith IE, Reis-Filho JS,. Triple-negative breast cancer. N Engl J Med 2010; 363: 1938-48.
15. Guo L, Choufani S, Ferreira J, et al., Altered gene expression and methylation of the human chromosome 11 imprinted region in small for gestational age (SGA) placentae. Dev Biol 2008; 320: 79-91.
16. Ito Y, Koessler T, Ibrahim AE, et al., Somatically acquired hypomethylation of IGF2 in breast and colorectal cancer. Hum Mol Genet 2008; 17: 2633-43.
17. Woodfine K, Huddleston JE, Murrell A,. Quantitative analysis of DNA methylation at all human imprinted regions reveals preservation of epigenetic stability in adult somatic tissue. Epigenet Chromatin 2011; 4: 1.
18. Barault L, Ellsworth RE, Harris HR, et al., Leukocyte DNA as surrogate for the evaluation of imprinted loci methylation in mammary tissue DNA. PLoS One 2013; 8: e55896.
19. Bediaga NG, Acha-Sagredo A, Guerra I, et al., DNA methylation epigenotypes in breast cancer molecular subtypes. Breast Cancer Res 2010; 12: R77.
20. Fackler MJ, Umbricht CB, Williams D, et al., Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. Cancer Res 2011; 71: 6195-207.
21. Chao HH, Zhang XF, Chen B, et al., Bisphenol A exposure modifies methylation of imprinted genes in mouse oocytes via the estrogen receptor signaling pathway. Histochem Cell Biol 2012; 137: 249-59.
22. Cui M, Wen Z, Yang Z, et al., Estrogen regulates DNA methyltransferase 3B expression in Ishikawa endometrial adenocarcinoma cells. Mol Biol Rep 2009; 36: 2201-7.
23. Shi JF, Li XJ, Si XX, et al., ERα positively regulated DNMT1 expression by binding to the gene promoter region in human breast cancer MCF-7 cells. Biochem Biophys Res Commun 2012; 427: 47-53.
24. Takeo C, Ikeda K, Horie-Inoue K, et al., Identification of Igf2, Igfbp2 and Enpp2 as estrogen-responsive genes in rat hippocampus. Endocr J 2009; 56: 113-20.
25. Zhang XF, Zhang LJ, Feng YN, et al., Bisphenol A exposure modifies DNA methylation of imprint genes in mouse fetal germ cells. Mol Biol Rep 2012; 39: 8621-8.
26. Rodriguez BA, Weng YI, Liu TM, et al., Estrogen-mediated epigenetic repression of the imprinted gene cyclin-dependent kinase inhibitor 1C in breast cancer cells. Carcinogenesis 2011; 32: 812-21.
27. Weaver JR, Sarkisian G, Krapp C, et al., Domain-specific response of imprinted genes to reduced DNMT1. Mol Cell Biol 2010; 30: 3916-28.
28. Li L, Lee KM, Han W, et al,. Estrogen and progesterone receptor status affect genome-wide DNA methylation profile in breast cancer. Hum Mol Genet 2010; 19: 4273-7.
29. Alvi MA, Liu X, O'Donovan M, et al., DNA methylation as an adjunct to histopathology to detect prevalent, inconspicuous dysplasia and early-stage neoplasia in Barrett's esophagus. Clin Cancer Res 2013; 19: 878-88.
30. Kamikihara T, Arima T, Kato K, et al., Epigenetic silencing of the imprinted gene ZAC by DNA methylation is an early event in the progression of human ovarian cancer. Int J Cancer 2005; 115: 690-700.
31. Prabhu JS, Wahi K, Korlimarla A, et al., The epigenetic silencing of the estrogen receptor (ER) by hypermethylation of the ESR1 promoter is seen predominantly in triple-negative breast cancers in Indian women. Tumour Biol 2012; 33: 315-23.
32. Chik F, Machnes Z, Szyf M,. Synergistic anti-breast cancer effect of a combined treatment with the methyl donor S-adenosyl methionine and the DNA methylation inhibitor 5-aza-2'-deoxycytidine. Carcinogenesis 2014; 35: 138-44.
33. Teschendorff AE, Menon U, Gentry-Maharaj A, et al., An epigenetic signature in peripheral blood predicts active ovarian cancer. PLoS One 2009; 4: e8274.
34. Baba Y, Nosho K, Shima K, et al., Hypomethylation of the IGF2 DMR in colorectal tumors, detected by bisulfite pyrosequencing, is associated with poor prognosis. Gastroenterology 2010; 139: 1855-64.
35. Brennan K, Garcia-Closas M, Orr N, et al., Intragenic ATM methylation in peripheral blood DNA as a biomarker of breast cancer risk. Cancer Res 2012; 72: 2304-13.
36. Widschwendter M, Apostolidou S, Raum E, et al., Epigenotyping in peripheral blood cell DNA and breast cancer risk: a proof of principle study. PLoS One 2008; 3: e2656.
37. Barbaux S, Gascoin-Lachambre G, Buffat C, et al., A genome-wide approach reveals novel imprinted genes expressed in the human placenta. Epigenetics 2012; 7: 1079-90.
38. Blagitko N, Mergenthaler S, Schulz U, et al., Human GRB10 is imprinted and expressed from the paternal and maternal allele in a highly tissue- and isoform-specific fashion. Hum Mol Genet 2000; 9: 1587-95.
39. Yoshihashi H, Maeyama K, Kosaki R, et al., Imprinting of human GRB10 and its mutations in two patients with Russell-Silver syndrome. Am J Hum Genet 2000; 67: 476-82.
40. Murphy SK, Huang Z, Wen Y, et al., Frequent IGF2/H19 domain epigenetic alterations and elevated IGF2 expression in epithelial ovarian cancer. Mol Cancer Res 2006; 4: 283-92.
41. Dowdy SC, Gostout BS, Shridhar V, et al., Biallelic methylation and silencing of paternally expressed gene 3 (PEG3) in gynecologic cancer cell lines. Gynecol Oncol 2005; 99: 126-34.
42. Pedersen IS, Dervan PA, Broderick D, et al., Frequent loss of imprinting of PEG1/MEST in invasive breast cancer. Cancer Res 1999; 59: 5449-51.
43. Kondo M, Suzuki H, Ueda R, et al., Frequent loss of imprinting of the H19 gene is often associated with its overexpression in human lung cancers. Oncogene 1995; 10: 1193-8.
44. Cui H, Onyango P, Brandenburg S, et al., Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2. Cancer Res 2002; 62: 6442-6.
45. Tian F, Tang Z, Song G, et al., Loss of imprinting of IGF2 correlates with hypomethylation of the H19 differentially methylated region in the tumor tissue of colorectal cancer patients. Mol Med Rep 2012; 5: 1536-40.
46. Shetty PJ, Movva S, Pasupuleti N, et al., Regulation of IGF2 transcript and protein expression by altered methylation in breast cancer. J Cancer Res Clin Oncol 2011; 137: 339-45.
47. Hartmann LC, Sellers TA, Frost MH, et al., Benign breast disease and the risk of breast cancer. N Engl J Med 2005; 353: 229-37.
48. McCann AH, Miller N, O'Meara A, et al., Biallelic expression of the IGF2 gene in human breast disease. Hum Mol Genet 1996; 5: 1123-7.
49. Heaphy CM, Bisoffi M, Fordyce CA, et al., Telomere DNA content and allelic imbalance demonstrate field cancerization in histologically normal tissue adjacent to breast tumors. Int J Cancer 2006; 119: 108-16.